Verseau Therapeutics is a pioneering brand revolutionizing cancer treatment through the repolarization of macrophages. By stimulating the conversion of immuno-suppressive and pro-tumorigenic M2 macrophages into pro-inflammatory M1 macrophages, Verseau is driving a coordinated immune response to combat cancer. Using their innovative and proprietary human-based discovery engine, they have successfully identified and validated over 20 targets for regulating macrophage biology.

Their cutting-edge science has led to the development of two lead programs, targeting PSGL-1 and VSIG4, which are rapidly progressing towards clinical trials. With a strong commitment to scientific advancement, Verseau Therapeutics is at the forefront of developing a new class of cancer immunotherapies. To learn more about Verseau's groundbreaking research and their transformative approach to cancer treatment, visit their website